**ON CAM**

Another success story for Malaysia’s biopharma company.

Cambridge Biotek Sdn Bhd is set to raise some 200 million ringgit from its listing on the Bursa Malaysia ACE Market by 2020.

The money raised from the lisitng will be used as capital expenditure to grow its business.

**VO**

Cambridge Biotek Founder Dr Nabisar Mustan says the company has been strategising its route to listing over the past three years.

However, she did not rule out the possibility that the listing may be done as early as this year.

**SOT 1**

**TC IN: 42:00**"We are looking at a year plus to two we should have listed. Because we need to raise the money because we are at a level where we will go to another leap only by finishing our clinical studies.”

**TC OUT: 42:15**

**SUPER: DR NABISAR MUSTAN/ FOUNDER OF CAMBRIDGE BIOTEK**

Dr Nabisar was speaking to reporters at a media familiarisation tour organised by Bioeconomy Corporation in Sungai Buloh on Wednesday.

The tour aims to create awareness and understanding among members of the media on the importance of BioNexus status companies to the country’s national economy.

They were given a tour of Cambridge Biotek’s facility and witnessed the official handover of the BioNext report to the company.

Cambridge Biotek has completed the BioNext Programme, a joint initiative by Bioeconomy Corp and SME Corp Malaysia to accelerate the development of 20 home grown champions in the bio-based sector.

Dr Nabisar says the programme places the company in a strong position and allows it to utilise proceeds from the listing for preclinical product specificity study, staff recruitment and to establish a strong marketing team.

The company has 47 products in 15 categories and is confident of earning revenue of 5 million ringgit in the 2017 financial year.

**SOT 2**

**TC IN: 48:36**

“This year we are looking at 5 mil because previously we were doing like 3 million before and because of GST we dipped, and now it’s coming back… and hopefully we can finish up with a note of 5 mil. But with the injection of funding where we have more marketing, senior marketing people coming onboard and specialise in this area, I think we can go much further.”

**TC OUT: 49:03**
**SUPER: DR NABISAR MUSTAN/ FOUNDER OF CAMBRIDGE BIOTEK**

Cambridge Biotek’s best-selling products included Phytoheat, an anti-inflammatory agent; Phytocool, a non-steroidal product that relieves sinusitis; as well as Denpro, which fights dengue.

Bioeconomy Corp has nurtured 280 BioNexus status companies, of which 53 are involved in natural products discovery and commercialisation, as at February 2017.

Twenty high potential BioNexus status companies, particularly small and medium enterprises involved in the natural products sector, were chosen for the BioNext programme.

**ENDS**